Aved Products Recall - Unauthorized Ophthalmic Solutions
Summary
Health Canada issued a Type III recall for Aved ophthalmic solutions from Labtician Ophthalmics, Inc. Nine products were sold without market authorization (DIN) in Canada due to third-party branding issues. Affected products include various atropine sulfate solutions (0.01%-0.05%), fluorescein/proparacaine, insulin ophthalmic, mitomycin, moxifloxacin, and combination steroid/antibiotic solutions. Distribution is national in Canada with recall classification RA-81839.
What changed
Health Canada has issued a Type III recall for Aved ophthalmic solutions manufactured by Labtician Ophthalmics, Inc. Nine products lack market authorization (DIN) due to third-party branding and are being removed from the Canadian market. Affected products span multiple ophthalmic formulations including atropine sulfate solutions (0.01%, 0.02%, 0.025%, 0.05%), fluorescein/proparacaine combination, insulin regular ophthalmic, mitomycin 0.04%, moxifloxacin injection, and prednisolone/moxifloxacin/bromfenac combination. Retailers and healthcare establishments nationwide are affected.
Healthcare providers and retailers should verify inventory for affected products using the lot numbers provided (ranging from October 2025 through February 2026). Patients using these products should consult their healthcare provider before discontinuing use. Adverse reactions and safety complaints should be reported to Health Canada via the MedEffect Canada portal.
What to do next
- Verify inventory for affected Aved ophthalmic products by lot number
- Advise patients not to discontinue affected products without consulting healthcare provider
- Report any adverse reactions or health product safety complaints to Health Canada
Archived snapshot
Apr 3, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Health product recall
Aved products recall: No market authorization
Brand(s)
Last updated
2026-04-02
Summary
Product Various Ophthalmic Solutions from Aved Issue Health products - Unauthorized product What to do Consult your health care professional if you have any health concerns.
Distribution National
Affected products
| Brand | Product Name | Market Authorization | Dosage Form | Strength | Lot Number |
|---|---|---|---|---|---|
| Labtician Ophthalmics, Inc. / Aved | Atropine Sulfate 0.01% Ophthalmic Solution, 5 mL | No market authorization | Solution | Atropine Sulfate 0.01% | 11122025@5, 01052026@11 |
| Labtician Ophthalmics, Inc. / Aved | Atropine Sulfate 0.02% Ophthalmic Solution, 5 mL | No market authorization | Solution | Atropine Sulfate 0.02% | 10162025@3, 12052025@5, 01272026@13 |
| Labtician Ophthalmics, Inc. / Aved | Atropine Sulfate 0.025% Ophthalmic Solution, 5 mL | No market authorization | Solution | Atropine Sulfate 0.025% | 10162025@5, 12082025@12, 01272026@14, 02252026@5 |
| Labtician Ophthalmics, Inc. / Aved | Atropine Sulfate 0.05% Ophthalmic Solution, 5 mL | No market authorization | Solution | Atropine Sulfate 0.05% | 10022025@3, 11202025@8, 01152026@6, 02042026@14 |
| Labtician Ophthalmics, Inc. / Aved | Fluorescein Na 0.25% / Proparacaine HCl 0.5% Ophthalmic Solution, 5 mL | No market authorization | Solution | Fluorescein Na 0.25% / Proparacaine HCl 0.5% | 11202025@5, 12082025@11, 12232025@2, 01212026@10 |
| Labtician Ophthalmics, Inc. / Aved | Insulin Regular (Human) 25 IU/mL Ophthalmic Solution, 10 mL | No market authorization | Solution | Insulin 25 IU/mL | 10232025@3, 11142025@4, 12112025@3, 01222026@8 |
| Labtician Ophthalmics, Inc. / Aved | Mitomycin 0.04% Ophthalmic Solution (PF), 0.75 mL | No market authorization | Solution | Mitomycin 0.04% | 01192026@8 |
| Labtician Ophthalmics, Inc. / Aved | Moxifloxacin HCl 150 mcg/0.1 mL Ophthalmic Injection Solution, 0.75 mL | No market authorization | Solution | Moxifloxacin HCl 150 mcg/0.1 mL | 01192026@8 |
| Labtician Ophthalmics, Inc. / Aved | Prednisolone Sodium Phosphate 1% / Moxifloxacin 0.5% / Bromfenac 0.075% | No market authorization | Solution | Prednisolone Sodium Phosphate 1%/Moxifloxacin 0.5%/Bromfenac 0.075% | 12162026@11 |
Issue
Products sold without market authorization (DIN) in Canada due to third-party branding.
What you should do
- Verify if your product is affected.
- Consult your healthcare provider prior to discontinuing use of the affected product(s), or for any health concerns.
- Contact the recalling firm if you have any questions about the recall.
- Report any health product related side effects to Health Canada.
- Report any other health product safety complaints to Health Canada.
Additional information
Background
Depth of recall: Retailers, Health Care Establishments
Details
Original published date:
2026-04-02
Alert / recall type Health product recall Category Health products - Drugs Companies Aved
44 Richmond St. West, Unit 202,
Oshawa, Ontario, L1G 1C7
Published by Health Canada Audience General public Healthcare Industry Distribution National Recall class Type III Identification number RA-81839
Get notified
Receive emails about new and updated recall and safety alerts.
Related changes
Get daily alerts for Health Canada Recalls & Safety Alerts
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from Health Canada.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when Health Canada Recalls & Safety Alerts publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.